^
+ Follow MEDICINAL PRODUCTS Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 568687 [Title] => Roche's lung cancer drug receives positive opinion in Europe [Summary] =>

Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.

[DatePublished] => 2010-04-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1475655 [AuthorName] => LPM [SectionName] => Cebu News [SectionUrl] => cebu-news [URL] => ) [2] => Array ( [ArticleID] => 302759 [Title] => ‘Exubera’ gets positive opinion from EMEA [Summary] => PARIS — Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
MEDICINAL PRODUCTS
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 731565
                    [Title] => Treatment for advanced ovarian  cancer receives positive opinion
                    [Summary] => 

BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.

[DatePublished] => 2011-09-29 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 568687 [Title] => Roche's lung cancer drug receives positive opinion in Europe [Summary] =>

Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.

[DatePublished] => 2010-04-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1475655 [AuthorName] => LPM [SectionName] => Cebu News [SectionUrl] => cebu-news [URL] => ) [2] => Array ( [ArticleID] => 302759 [Title] => ‘Exubera’ gets positive opinion from EMEA [Summary] => PARIS — Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with